Q4 2024 · 13F-HR
MPM BioImpact LLCholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002794
$704.4M
Reported value
47
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 230031106 | CGEM | Cullinan Therapeutics, Inc. | $93.2M | 13.2% | 7,648,268 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals Inc. | $31.5M | 4.48% | 617,035 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics Inc | $28.8M | 4.09% | 1,079,316 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $26.9M | 3.82% | 389,611 | Common | SOLE |
| 632307104 | NTRA | Natera Inc | $25.4M | 3.61% | 160,626 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $24.4M | 3.46% | 589,579 | Common | SOLE |
| 254604101 | IRON | Disc Medicine Inc | $22.0M | 3.12% | 346,401 | Common | SOLE |
| 516544103 | LNTH | Lantheus Holdings Inc | $21.1M | 3.00% | 236,213 | Common | SOLE |
| 98887Q104 | ZLAB | Zai Lab Ltd | $21.0M | 2.97% | 800,000 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $20.4M | 2.90% | 702,981 | Common | SOLE |
| 462260100 | IOVA | Iovance Biotherapeutics Inc | $19.8M | 2.81% | 2,673,905 | Common | SOLE |
| 69366J200 | PTCT | PTC Therapeutics Inc | $19.6M | 2.79% | 434,767 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences PTE LTD | $18.4M | 2.62% | 1,489,237 | Common | SOLE |
| 80706P103 | SRRK | Scholar Rock Holding Corp. | $18.0M | 2.55% | 416,144 | Common | SOLE |
| 61559X104 | MLTX | Moonlake Immunotherapeutics | $17.1M | 2.42% | 315,230 | Common | SOLE |
| 68062P106 | OLMA | Olema Pharmaceuticals, Inc. | $17.0M | 2.41% | 2,912,550 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc | $16.5M | 2.34% | 391,018 | Common | SOLE |
| 21077P108 | CNTX | Context Therapeutics Inc | $15.4M | 2.19% | 14,705,882 | Common | SOLE |
| 40131M109 | GH | Guardant Health Inc | $13.8M | 1.96% | 452,739 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $13.7M | 1.95% | 313,817 | Common | SOLE |
| 46565G104 | 5E7 | iTeos Therapeutics, Inc. | $13.4M | 1.90% | 1,745,943 | Common | SOLE |
| 816212302 | RNAC | Cartesian Therapeutics Inc | $12.9M | 1.83% | 721,139 | Common | SOLE |
| 77313F106 | RCKT | Rocket Pharmaceuticals, Inc. | $12.8M | 1.82% | 1,020,559 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics Inc | $12.8M | 1.82% | 460,617 | Common | SOLE |
| 89532M101 | TRVI | Trevi Therapeutics Inc | $12.8M | 1.81% | 3,094,896 | Common | SOLE |
| 90184D100 | TWST | Twist Bioscience Corp | $12.4M | 1.76% | 267,497 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $12.4M | 1.76% | 8,567,896 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $12.3M | 1.75% | 230,000 | Common | SOLE |
| 76029N106 | REPL | Replimune Group Inc | $11.5M | 1.63% | 950,000 | Common | SOLE |
| 67080N101 | NUVB | Nuvation Bio Inc | $11.1M | 1.57% | 4,164,178 | Common | SOLE |
| 92337R101 | VERA | Vera Therapeutics Inc. | $10.9M | 1.55% | 257,788 | Common | SOLE |
| 45166A102 | IDYA | Ideaya Biosciences, Inc. | $10.6M | 1.51% | 414,035 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics Inc. | $9.3M | 1.33% | 2,268,825 | Common | SOLE |
| 91307C102 | UTHR | United Therapeutics Corp. | $8.1M | 1.15% | 23,000 | Common | SOLE |
| 03969T109 | ARCT | Arcturus Therapeutics Holdings | $7.8M | 1.11% | 459,943 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc | $7.7M | 1.10% | 197,212 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics Inc | $7.6M | 1.07% | 685,826 | Common | SOLE |
| 03843E104 | AQST | Aquestive Therapeutics Inc | $5.7M | 0.81% | 1,611,833 | Common | SOLE |
| 05464T104 | AXSM | Axsome Therapeutics Inc | $4.2M | 0.60% | 50,000 | Common | SOLE |
| 869367102 | — | Sutro Biopharma, Inc. | $4.0M | 0.56% | 2,160,062 | Common | SOLE |
| 95075A107 | HOWL | Werewolf Therapeutics, Inc. | $3.5M | 0.50% | 2,388,011 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics Inc | $3.5M | 0.49% | 559,547 | Common | SOLE |
| 98943L107 | ZNTL | Zentalis Pharmaceuticals, Inc. | $3.4M | 0.48% | 1,106,851 | Common | SOLE |
| 92536C103 | VERUEUR | Veru Inc. | $2.8M | 0.40% | 4,285,365 | Common | SOLE |
| 00653A107 | ADAPY | Adaptimmune Therapeutics plc | $2.7M | 0.39% | 5,095,912 | Common | SOLE |
| 00166B105 | ALXO | ALX Oncology Holdings Inc. | $2.3M | 0.33% | 1,391,434 | Common | SOLE |
| 760273102 | RPTX | Repare Therapeutics, Inc. | $1.6M | 0.23% | 1,231,154 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.